Jeff Yass’s Candel Therapeutics CADL Stock Holding History

Jeff Yass’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.35M	Buy	227,939 +114,966	+102%	+$868K	﹤0.01%	6109
2026 Q1	$554K	Sell	112,973 -24,435	-18%	-$133K	﹤0.01%	9392
2025 Q4	$776K	Sell	137,408 -86,413	-39%	-$465K	﹤0.01%	7760
2025 Q3	$1.14M	Sell	223,821 -129,477	-37%	-$748K	﹤0.01%	7029
2025 Q2	$1.79M	Buy	353,298 +112,123	+46%	+$577K	﹤0.01%	6039
2025 Q1	$1.36M	Sell	241,175 -53,268	-18%	-$435K	﹤0.01%	6464
2024 Q4	$2.56M	Buy	294,443 +158,988	+117%	+$939K	﹤0.01%	4774
2024 Q3	$939K	Buy	+135,455	New	+$841K	﹤0.01%	6933

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jeff Yass's CADL Position: Q2 2026 in Review

Jeff Yass increased its Candel Therapeutics (CADL) stake by 102% in Q2 2026, buying an estimated $868K and bringing the position to 227,939 shares worth $2.35M. The position accounts for ﹤0.01% of the portfolio, ranked #6109.

Jeff Yass first reported a position in CADL in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.56M in Q4 2024. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Jeff Yass held 227,939 shares of Candel Therapeutics worth $2.35M as of Q2 2026.
Jeff Yass bought 114,966 Candel Therapeutics shares in Q2 2026, an estimated $868K.
Candel Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6109 holding.
Jeff Yass first reported a position in Candel Therapeutics in Q3 2024 and has held it in 8 quarters since.
Jeff Yass's Candel Therapeutics position peaked at $2.56M in Q4 2024.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.